JCOG2502: A phase III trial comparing osimertinib and durvalumab following chemoradiotherapy for patients with unresectable locally advanced non-small cell lung cancer harboring EGFR mutations

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2026
This article has no abstract
Epistemonikos ID: baedf870f25479b4ad03ae529b9e6d5c37a3911a
First added on: Aug 10, 2026